Stock CHM CHIMERIC THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Chimeric Therapeutics Limited

Equities

CHM

AU0000121576

Market Closed - Australian S.E.
Other stock markets
 02:10:42 2024-05-02 EDT 		5-day change 1st Jan Change
0.029 AUD +7.41% Intraday chart for Chimeric Therapeutics Limited 0.00% -17.14%
02:38am Chimeric Therapeutics Appoints COO; Shares Rise 4% MT
05-01 Chimeric Therapeutics' CEO/Managing Director Steps Down; Shares Plunge 20% MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Chimeric Therapeutics Appoints COO; Shares Rise 4%
MT
Chimeric Therapeutics' CEO/Managing Director Steps Down; Shares Plunge 20%
MT
Chimeric Therapeutics Obtains Patent Application Covering CORE-NK Technology; Shares Up 3%
MT
Chimeric Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Chimeric Therapeutics Treats First Patient in Phase 1B Leukemia Trial
MT
Chimeric Therapeutics to Raise AU$3.2 Milion Via Shortfall Placement
MT
Chimeric Therapeutics Opens Phase 1B Leukemia Trial
MT
Chimeric Therapeutics Receives AU$7 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6%
MT
Chimeric Therapeutics Secures AU$1 Million via Share Placement Deal
MT
Chimeric Therapeutics Extends Closing Date of AU$10 Million Entitlement Offer
MT
Chimeric Therapeutics Doses First Patient in Phase 1B Clinical Trial for Brain Cancer
MT
Chimeric Therapeutics Announces FDA Clearance of IND Application for CHM 2101
CI
Australian Shares Rebound Ahead of US Fed Policy Meeting
MT
US FDA Gives Green Signal to Chimeric Therapeutics' IND Application for Gastrointestinal Cancer Drug; Shares Jump 65%
MT
Chimeric Therapeutics to Raise AU$10 Million from Entitlement Offer
MT
Chimeric Therapeutics Signs Deal to Support Leukemia Trial
MT
Chimeric Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Chimeric Therapeutics Limited Announces Board Changes
CI
Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive Director
CI
Chimeric Therapeutics Secures Japanese Patent Allowance for Chlorotoxin
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CHM Stock
  4. News Chimeric Therapeutics Limited